Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene expression profiling in acute myeloid leukemia.

Lars Bullinger1, Peter J M Valk

  • 1Department of Internal Medicine III, University of Ulm, Robert-Koch-Str 8, D-89081 Ulm, Germany. lars.bullinger@medizin.uni-ulm.de

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|September 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients.

Blood advances·2026
Same author

Publisher Correction: Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia.

Genome biology·2026
Same author

Kidney Transplantation after Clearing Anti-HLA Antibodies with CD19 CAR T Cells.

The New England journal of medicine·2026
Same author

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.

Bone marrow transplantation·2026
Same author

A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity-ECOG-Age criteria.

British journal of haematology·2026
Same author

Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.

Blood·2026

Gene expression profiling advances acute myeloid leukemia (AML) research by refining diagnosis and predicting outcomes. This technology aids in classifying AML subtypes and understanding its complex biology.

Area of Science:

  • Genomics
  • Molecular Biology
  • Hematology

Background:

  • Significant progress in understanding and treating acute myeloid leukemia (AML) has been made.
  • The World Health Organization (WHO) classification incorporates diverse features to define AML entities.
  • Existing cytogenetic subgroups show heterogeneity, and the pathogenic events in many AML subtypes remain unknown.

Purpose of the Study:

  • To explore the potential of novel genomic approaches, specifically DNA microarray technology, for refining AML studies.
  • To highlight the value of gene expression profiling in AML diagnosis, subclass discovery, and outcome prediction.

Main Methods:

  • Utilizing DNA microarray technology to survey gene expression levels in parallel.
  • Applying gene expression profiling to diagnose cytogenetic subtypes and identify novel AML subclasses.

Related Experiment Videos

  • Combining gene expression profiling with other microarray-based applications, high-throughput mutational analyses, and proteomic approaches.

    • Main Results:

    • Gene expression profiling in AML is established and valuable for diagnosis and prognosis.
    • Studies show a high concordance of findings in gene expression profiling, suggesting a refined molecular taxonomy.
    • These approaches contribute to classification, therapeutic decision-making, and understanding AML pathobiology.

    Conclusions:

    • Gene expression profiling offers a powerful tool for advancing AML research and clinical practice.
    • Further integration of genomic and proteomic approaches will enhance the molecular understanding and treatment of AML.
    • Continued research promises a more precise molecular classification and improved patient outcomes for acute myeloid leukemia.